Ash Alizadeh

Ash Alizadeh co-invented the CAPP-Seq technology for ultrasensitive ctDNA detection and has led its clinical application for monitoring treatment response in lymphoma and lung cancer, establishing ctDNA-based molecular response definitions that predict patient outcomes independently of imaging assessments. His research at Stanford has demonstrated that ctDNA dynamics during the first cycles of therapy can identify patients likely to achieve durable remissions versus those requiring treatment intensification. His work has been instrumental in defining ctDNA as a quantitative biomarker for real-time therapy monitoring across multiple cancer types.